Can we get a picture with you?
Thank you very much.
OK. All right.
Absolutely.
All right.
…can run.
And then the imagination…
Got it. It makes sense. Once you have a mechanism to legitimize data, that’s when you can start?
…makes sense.
Not at all?
OK. By the way, with regards to digital therapeutics, who do you think I should be working with? Obviously, this is NHI, but even before NHI, because, again, it’s digital. Is this something I can work on with your office or keep working with the NDC before working with NHI? ...
Yeah.
That’s something we will do.
Or just write it into the treatment history.
Serve individual patients better, based on the data that we can get off the user…
We will participate on the health topics.
One last point. We took a look at the Presidential Hackathon.
Which is the opposite. It’s the opposite.
De-identification in Mandarin is what, 去識別化?
Through the legislators?
Interesting. All right. Is there anything else that you think that this country should be focused on with regards to health data?
Simple language.
Gain in return, yeah.
Computation bragging rights.
or train tickets.
Very hard.
For masks, yeah.
Servers.
Last night. [laughs]
True.
Those are the two things. The blockchain infrastructure on personal health data, and digital therapeutics is what we will continue to focus on. For however many years that may take us.
We think that Taiwan is a country that has an edge, because of what you mentioned 30 minutes ago, NHI, good practice, and the fact that we have data.
But because digital service is localized, is customized, that will not be the model like that of traditional molecules. There will be regional solutions, jurisdictional solutions that are created that can then be used in that region.
One of the things that I’m working with the National Development Council and NHI on, maybe we can get your support as well, is this helping Taiwan create a digital therapeutics industry. Again, traditional pharmaceuticals, molecules, created in Switzerland or created in New Jersey, at headquarters, sold around the world.
Exactly. Those are the main two things that we’re working on.
Then how do we give consent and even the economics as part of sharing economics back with the individual user…. That was the idea of working with Bitmark as a blockchain to capture legitimacy, integrity.
That’s what we’re trying to do in Taiwan. That’s one thing. As a result of capturing more data, then comes through my story of why we’re working with Sean. As we collect more data, these pharmaceuticals or these third parties, in order to do further research, would want access to ...
Now, we were looking at a recent legislation in Germany, starting in April 2020, their equivalent of the FDA will basically approve apps and enable healthcare providers to prescribe the apps. This is the Digital Care Act.
We’re trying to create a digital therapeutic that can make health care providers more efficient, save NHI money. That’s one thing.
Number three, spending, third, spending, diabetes. The fifth spending is hypertension, seven and eight, stroke and cardiac arrest. One, three, five, seven, eight, are all chronic disease related.
Number one, and half of chronic kidney conditions are a result of diabetes.
Chronic kidney.
Now, before I go into the health data again, the whole idea about digital therapeutics is our number one chronic disease is chronic kidney related.
Then when the patients use our app, they get education, they get support on managing diabetes. That’s what we do.
As the data starts coming up, we then run these algorithms and alert the doctors. Then the doctors make decisions.
Right. As a business, that’s our strategy.
I wouldn’t say de facto yet, we’re trying to be.
Somebody needs to go out and do this.
